REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $281 | -35.7% | 24,527 | +41.9% | 0.02% | -36.8% |
| Q2 2023 | $437 | -14.6% | 17,285 | +8.8% | 0.04% | -7.3% |
| Q1 2023 | $512 | +82.9% | 15,881 | +4.5% | 0.04% | +57.7% |
| Q4 2022 | $280 | -99.9% | 15,193 | -7.4% | 0.03% | -39.5% |
| Q3 2022 | $443,000 | +58.2% | 16,410 | -19.0% | 0.04% | +53.6% |
| Q2 2022 | $280,000 | -30.5% | 20,248 | -2.1% | 0.03% | -12.5% |
| Q1 2022 | $403,000 | +18.2% | 20,690 | -0.9% | 0.03% | +23.1% |
| Q4 2021 | $341,000 | -76.1% | 20,878 | -59.2% | 0.03% | -78.3% |
| Q3 2021 | $1,427,000 | -3.4% | 51,220 | +2.8% | 0.12% | -3.2% |
| Q2 2021 | $1,477,000 | +4.5% | 49,817 | -1.5% | 0.12% | -10.8% |
| Q1 2021 | $1,414,000 | -7.3% | 50,577 | -6.1% | 0.14% | -13.7% |
| Q4 2020 | $1,526,000 | -0.3% | 53,839 | -11.6% | 0.16% | -24.1% |
| Q3 2020 | $1,531,000 | – | 60,914 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NovaQuest Capital Management, L.L.C. | 1,558,426 | $48,000,000 | 65.50% |
| Essex Woodlands Management, Inc. | 3,842,047 | $118,335,000 | 25.90% |
| Rhenman & Partners Asset Management AB | 203,181 | $6,258,000 | 0.77% |
| EAM Global Investors LLC | 44,898 | $1,383,000 | 0.72% |
| Fosun International Ltd | 319,313 | $9,835,000 | 0.62% |
| EAM Investors, LLC | 113,096 | $3,483,000 | 0.58% |
| ArrowMark Colorado Holdings LLC | 1,735,699 | $53,460,000 | 0.53% |
| Perceptive Advisors | 618,957 | $19,064,000 | 0.53% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 111,360 | $3,430,000 | 0.45% |
| Schonfeld Strategic Advisors LLC | 83,700 | $2,578,000 | 0.19% |